ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2187

Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Abstract Number: 1585

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Abstract Number: 1538

Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Abstract Number: 1748

Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
Abstract Number: 2214

Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
Abstract Number: 0032

Defective Chaperone-mediated Autophagy Is a Hallmark of Joint Disease in Patients with Knee Osteoarthritis
Abstract Number: 1180

Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis
Abstract Number: 0591

Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis
Abstract Number: 1717

Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli
Abstract Number: 1916

Defining Early-stage Knee Osteoarthritis: A Scoping Review
Abstract Number: 0096

Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
Abstract Number: 0930

Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Abstract Number: 1451

Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Abstract Number: 0098

Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 1481

Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].